The Comparison of Sensitivity and Specificity of ELISA-based Microneutralization Test with Hemagglutination Inhibition Test to Evaluate Neutralizing Antibody against Influenza Virus (H1N1)
AbstractBackground: The most common serological assay to measure anti-influenza antibodies is hemagglutination inhibition (HI) assay. Recently, neutralizing antibodies against influenza virus infection or vaccination can also be detected using microneutralization assays and occasionally, have greater sensitivity than the standard HI assays. The study aimed to compare the sensitivity and specificity of ELISA-based microneutralization (microNT-ELISA) and conventional HI assays in order to detect influenza H1N1 virus antibodies.Methods: MicroNT-ELISA was set up according to the WHO Manual on Influenza Diagnosis and Surveillance in Virology Department of Tehran University of Medical Sciences for the detection of neutralizing antibodies against H1N1 influenza virus in 2013. Fifty serum samples were analyzed with both HI and microNT-ELISA assays. Correlation between methods was calculated by linear regression analysis.Results: The linear correlation coefficient squares, R2, of microNT-ELISA and HI test was 0.61 (P<0.0001) and we observed a high index of coincidence between the two tests. According to McNemar's test, there was no statistically significant difference between these two assays (P>0.05).Conclusion: The sensitivity and specificity of microNT-ELISA assay were high (87% and 73%, respectively) and closely related to gold standard test results. Therefore, microNT-ELISA is recommended as an alternative or complementary test to conventional HI assay for serological and epidemiological purposes.
Katz JM, Hancock K, Xu X (2011). Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. Expert Rev Anti Infect Ther, 9 (6): 669-83.
Playford EG, Dwyer DE (2002). Laboratory diagno-sis of influenza virus infection. Pathology, 34 (2): 115-25.
Li ZN, Lin SC, Carney PJ, et al (2014). IgM, IgG, and IgA antibody responses to influenza A (H1N1) pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States. Clin Vaccine Immunol, 21 (8): 1054-60.
Trombetta CM, Montomoli E (2016). Influenza immunology evaluation and correlates of protec-tion: a focus on vaccines. Expert Rev Vaccines, 15 (8): 967-76.
Hirst GK (1941). The Agglutination of Red Cells by Allantoic Fluid of Chick Embryos Infected with Influenza Virus. Science, 94 (2427): 22-3.
Morokutti A, Redlberger-Fritz M, Nakowitsch S, et al (2013). Validation of the modified hemagglutina-tion inhibition assay (mHAI), a robust and sensi-tive serological test for analysis of influenza virus-specific immune response. J Clin Virol, 56 (4): 323-30.
Allwinn R, Preiser W, Rabenau H, et al (2002). Labor-atory diagnosis of influenza--virology or serology? Med Microbiol Immunol, 191 (3-4): 157-60.
Petric M, Comanor L, Petti CA (2006). Role of the laboratory in diagnosis of influenza during sea-sonal epidemics and potential pandemics. J Infect Dis, 194 Suppl 2:S98-110.
Rothbarth PH, Groen J, Bohnen AM, et al (1999). Influenza virus serology--a comparative study. J Virol Methods, 78 (1-2): 163-9.
Beyer WE, Palache AM, Luchters G, et al (2004). Se-roprotection rate, mean fold increase, seroconver-sion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res, 103 (1-2): 125-32.
Zakay-Rones Z (2010). Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines, 9 (12): 1423-39.
Ndifon W, Dushoff J, Levin SA (2009). On the use of hemagglutination-inhibition for influenza sur-veillance: surveillance data are predictive of influen-za vaccine effectiveness. Vaccine, 27 (18): 2447-52.
Stephenson I, Wood J, Nicholson K, et al (2004). Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res, 103 (1): 91-5.
Stephenson I, Wood JM, Nicholson KG, et al (2003). Sialic acid receptor specificity on erythro-cytes affects detection of antibody to avian influ-enza haemagglutinin. J Med Virol, 70 (3): 391-8.
Subbarao EK, Kawaoka Y, Ryan-Poirier K, et al (1992). Comparison of different approaches to measuring influenza A virus-specific hemaggluti-nation inhibition antibodies in the presence of se-rum inhibitors. J Clin Microbiol, 30 (4): 996-9.
Sui J, Hwang WC, Perez S, et al (2009). Structural and functional bases for broad-spectrum neutraliza-tion of avian and human influenza A viruses. Nat Struct Mol Biol, 16 (3): 265-73.
Rowe T, Abernathy RA, Hu-Primmer J, et al (1999). Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combi-nation of serologic assays. J Clin Microbiol, 37 (4): 937-43.
Gross P, Davis A (1979). Neutralization test in influ-enza: use in individuals without hemagglutination inhibition antibody. J Clin Microbiol, 10 (3): 382-4.
World Health Organization, Global influenza surveil-lance network (2011). Manual for the laboratory diagno-sis and virological surveillance of influenza. World Health Organization, Geneva, Switzerland, pp: 63-77.
Kitikoon P, Vincent AL (2014). Microneutralization assay for swine influenza virus in swine serum. Methods Mol Biol, 1161: 325-35.
Moghadami M, Moattari A, Tabatabaee HR, et al (2010). High titers of hemagglutination inhibition antibodies against 2009 H1N1 influenza virus in Southern Iran. Iran J Immunol, 7 (1): 39-48.
Reed LJ, Muench H (1938). A simple method of es-timating fifty per cent endpoints. Am J Epidemiol, 27 (3): 493-7.
Vemula SV, Zhao J, Liu J, et al (2016). Current Ap-proaches for Diagnosis of Influenza Virus Infec-tions in Humans. Viruses, 8 (4): 96.
Laurie KL, Engelhardt OG, Wood J, et al (2015). In-ternational Laboratory Comparison of Influenza Microneutralization Assays for A (H1N1) pdm09, A (H3N2), and A (H5N1) Influenza Viruses by CONSISE. Clin Vaccine Immunol, 22 (8): 957-64.
Tremblay CL, Rouleau D, Fortin C, et al (2011). Im-munogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine, 29 (7): 1359-63.
Stephenson I, Das RG, Wood JM, et al (2007). Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 vi-ruses: an international collaborative study. Vaccine, 25 (20): 4056-63.
Stephenson I, Heath A, Major D, et al (2009). Repro-ducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis, 15 (8): 1252-9.
Hinshaw VS, Webster RG, Easterday BC, et al (1981). Replication of avian influenza A viruses in mammals. Infect Immun, 34 (2): 354-61.
Profeta ML, Palladino G (1986). Serological evidence of human infections with avian influenza viruses. Brief report. Arch Virol, 90 (3-4): 355-60.
Cheng LW, Huang SW, Huang LM, et al (2012). Comparison of neutralizing and hemagglutina-tion-inhibiting antibody responses for evaluating the seasonal influenza vaccine. J Virol Methods, 182 (1-2): 43-9.
Heckler R, Baillot A, Engelmann H, et al (2007). Cross-protection against homologous drift vari-ants of influenza A and B after vaccination with split vaccine. Intervirology, 50 (1): 58-62.
Lavenu A, Valleron A-J, Carrat F (2004). Exploring cross-protection between influenza strains by an epidemiological model. Virus Res, 103 (1): 101-5.
Skowronski DM, De Serres G, Janjua NZ, et al (2012). Cross-reactive antibody to swine influenza A (H3N2) subtype virus in children and adults be-fore and after immunisation with 2010/11 triva-lent inactivated influenza vaccine in Canada, Au-gust to November 2010. Euro Surveill, 17 (4): pii=20066.
Mandelboim M, Bromberg M, Sherbany H, et al (2014). Significant cross reactive antibodies to in-fluenza virus in adults and children during a peri-od of marked antigenic drift. BMC Infect Dis, 14: 346.
Medeiros R, Escriou N, Naffakh N, et al (2001). Hemagglutinin residues of recent human A (H3N2) influenza viruses that contribute to the in-ability to agglutinate chicken erythrocytes. Virology, 289 (1): 74-85.